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Abstract
Alternative splicing (AS) provides a potent mechanism for increasing protein diversity and modulating gene expression
levels. How alternate splice sites are selected by the splicing machinery and how AS is integrated into gene regulation
networks remain important questions of eukaryotic biology. Here we report that polypyrimidine tract-binding protein 1
(Ptbp1/PTB/hnRNP-I) controls alternate 59 and 39 splice site (59ss and 39ss) usage in a large set of mammalian transcripts. A
top scoring event identified by our analysis was the choice between competing upstream and downstream 59ss (u59ss and
d59ss) in the exon 18 of the Hps1 gene. Hps1 is essential for proper biogenesis of lysosome-related organelles and loss of its
function leads to a disease called type 1 Hermansky-Pudlak Syndrome (HPS). We show that Ptbp1 promotes preferential
utilization of the u59ss giving rise to stable mRNAs encoding a full-length Hps1 protein, whereas bias towards d59ss
triggered by Ptbp1 down-regulation generates transcripts susceptible to nonsense-mediated decay (NMD). We further
demonstrate that Ptbp1 binds to pyrimidine-rich sequences between the u59ss and d59ss and activates the former site
rather than repressing the latter. Consistent with this mechanism, u59ss is intrinsically weaker than d59ss, with a similar
tendency observed for other genes with Ptbp1-induced u59ss bias. Interestingly, the brain-enriched Ptbp1 paralog Ptbp2/
nPTB/brPTB stimulated the u59ss utilization but with a considerably lower efficiency than Ptbp1. This may account for the
tight correlation between Hps1 with Ptbp1 expression levels observed across mammalian tissues. More generally, these
data expand our understanding of AS regulation and uncover a post-transcriptional strategy ensuring co-expression of a
subordinate gene with its master regulator through an AS-NMD tracking mechanism.
Citation: Hamid FM, Makeyev EV (2014) Regulation of mRNA Abundance by Polypyrimidine Tract-Binding Protein-Controlled Alternate 59 Splice Site Choice. PLoS
Genet 10(11): e1004771. doi:10.1371/journal.pgen.1004771
Editor: Emanuele Buratti, International Centre for Genetic Engineering and Biotechnology, Italy
Received May 26, 2014; Accepted September 22, 2014; Published November 6, 2014
Copyright:  2014 Hamid, Makeyev. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work was supported by the National Medical Research Council (NMRC/CBRG/0028/2013; EVM) and the Nanyang President Graduate Scholarship
(FMH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: eugene.makeyev@kcl.ac.uk
Introduction
Eukaryotes rely on post-transcriptional control of their gene
expression programs to a remarkable extent. A compelling
example of this trend is the ability of many mammalian transcripts
to undergo alternative splicing (AS) regulated by interplay between
RNA-encoded cis-elements and trans-acting factors [1–4]. Distinct
AS patterns include singular and mutually exclusive cassette exons,
alternative 59- and 39-terminal exons, intron retention events, and
alternate 59 and 39 splice site (59ss and 39ss) choice [1,5]. Of these,
the latter two categories (A5C and A3C), involve alternative
utilization of exonic termini and constitute a major part of tissue-
specific AS programs [6,7]. Many of these events are known to
have biologically and medically important functions (e.g., [8,9]
and references therein).
Several earlier studies have begun elucidating molecular
mechanisms involved in A5C regulation. Important factors
affecting recognition of 59ss include (1) intrinsic efficiencies, or
strengths with which these elements interact with the U1 snRNP
component of the spliceosome and (2) the presence of adjacent
splicing silencer or enhancer sequences that can modulate AS
outcomes by recruiting cognate trans-regulators [10]. A common
A5C regulation strategy relies on a splicing silencer positioned
between an upstream and a downstream 59ss alternatives (u59ss
and d59ss) [11,12]. This often stimulates the u59ss though silencer-
dependent repression of the competing d59ss [11,12]. However,
the situation is complicated by the fact that hnRNP family proteins
interacting with classical splicing silencers may additionally
activate splicing reaction when recruited downstream of a 59ss
[13]. Thus, hnRNP binding between u59ss and d59ss alternatives
could theoretically bias A5C towards the u59ss by either repressing
the d59ss, stimulating the u59ss or both. It is generally unclear
which of these three possibilities is realized in natural contexts
since most published studies on A5C regulation mechanisms rely
largely on recombinant or/and in vitro approaches [11–13].
Mounting evidence suggests that in addition to generating
multiple protein isoforms from a single gene [2,14] AS is widely
used to control gene expression levels [4,15,16]. A prevalent post-
transcriptional mechanism regulating mRNA abundance involves
coupling between AS and nonsense-mediated decay (NMD), a
PLOS Genetics | www.plosgenetics.org 1 November 2014 | Volume 10 | Issue 11 | e1004771
quality control mechanism targeting mRNAs containing prema-
ture translation termination codons (PTCs) for degradation
[17,18]. AS-NMD plays important roles in diverse biological
processes [19] including regulation of RNA-binding protein
expression [20,21], granulocyte development [22], axonal guid-
ance [23] and brain response to seizures [24].
An hnRNP family member called polypyrimidine tract-binding
protein 1 (Ptbp1/PTB/hnRNP I; [25,26]) is known to control
expression of several genes through AS-NMD. Ptbp1 homeostasis
in proliferating cells is maintained by an AS-NMD-mediated auto-
regulation mechanism [27]. Dampening Ptbp1 levels in neurons
by microRNA miR-124 triggers global changes in cellular AS
patterns and leads to increased expression of at least three AS-
NMD targets encoding brain-enriched Ptbp1 paralog Ptbp2/
nPTB/brPTB and post-synaptic proteins Gabbr1 and PSD-95/
Dlg4 [28–30]. These genes contain Ptbp1-repressible cassette
exons essential for open reading frame (ORF) integrity. Skipping
of these exons in the presence of Ptbp1 results in a frame-shift and
triggers NMD. On the other hand, their inclusion upon Ptbp1
down-regulation leads to accumulation of translationally active
mRNAs. It is currently unknown whether the repertoire of Ptbp1-
dependent AS-NMD targets is limited to brain-enriched mRNAs
or if it could additionally include other types of transcripts, e.g.
those undergoing down-regulation during nervous system devel-
opment.
Here we carried out a systematic analysis of transcriptome-wide
RNA sequencing (RNA-seq) data and uncovered a large repertoire
of Ptbp1-regulated A5C and A3C targets. Strikingly, one of the
newly identified A5C events participates in an unusual AS-NMD
circuitry controlling the abundance of mRNA encoding Hps1, a
subunit of the Rab32/38 guanine nucleotide exchange factor
(GEF) essential for biogenesis of lysosome-related organelles and
mutated in patients with Hermansky-Pudlak Syndrome (HPS;
OMIM: 203300; [31–34]). We describe the mechanistic under-
pinning of this regulation and provide evidence that this post-
transcriptional mechanism may play an important part in shaping
Hps1 tissue-specific expression patterns.
Results
Ptbp1 controls a number of alternate 59 and 39 splice site
events
To uncover additional Ptbp1 targets, we adapted a previously
described RNA-seq analysis algorithm relying on Fisher’s exact
test to identify significantly regulated A5C and A3C events (see
e.g., [35]; Fig. 1A). After confirming functionality of this approach
with training RNA-seq datasets from neuroblastoma CAD and
fibrosarcoma L929 cells (Fig. S1 and Tables S1 and S2) we
repeated the analysis for our RNA-seq datasets obtained for CAD
cells transfected with control siRNA, Ptbp1-specific siRNAs or a
mixture of siRNAs against Ptbp1 and its brain-enriched paralog
Ptbp2 with a largely overlapping AS regulation preferences
[26,36,37] (siControl, siPtbp1 and siPtbp1/2, respectively; [29];
NCBI Gene Expression Omnibus accession number GSE37933).
This identified 41 A5C and 52 A3C events consistently regulated
in both siPtbp1 and siPtbp1/2 samples (Fisher’s exact test p,0.05
and .5% difference in the percent spliced in statistic (y) [7];
Tables S3 and S4).
The newly identified targets belonged to diverse functional
categories and included amongst others regulators of transcription
(e.g., Chd3, Ezh2, Hmga1, Mef2a, Msx1, Ncoa7 and Prmt1) and
RNA metabolism (e.g., Hnrnpc, Hnrnph3, Larp4, Serbp1, Son,
Srsf5 and Ythdc1) (Tables S3 and S4). Several target genes such as
Enah, Hps1, Plekha6, Ssna1, Strn4 and Tjp1 were linked to
human diseases [32,33,38–42]. Comparable fractions of the AS
events were biased by Ptbp1 towards intron-distal (u59ss and d39ss)
or intron-proximal sites (d59ss and u39ss) and most of these
changes either altered ORF without introducing a premature
termination codon (PTC) or changed the 59UTR sequence
(Fig. 1B). For two disease-associated genes, Hps1 and Ssna1,
A5C was predicted to modulate mRNA abundance through AS-
NMD (Fig. 1B).
Of note, Ptbp1 had been previously proposed to regulate the
A5C event in the Usp5 gene identified by our analysis [43]. This
positive control and 11 examples of newly identified targets
representing the four AS patterns (Ptbp1-induced bias towards
u59ss, d59ss, u39ss or d39ss) were selected for RT-PCR validation.
Satisfyingly, all 12 genes showed readily detectable AS changes
upon Ptbp1 and Ptbp1/2 knockdown (Fig. 1C–D and Fig. S1B).
Ptbp1 knockdown accounted for most of the effect in all targets
except Usp5 where Ptbp2 contribution was substantial (Fig. S1B).
We concluded that Ptbp1 was involved in large-scale regulation of
A5Cs and A3Cs.
Ptbp1 regulates Hps1 expression through alternate 59ss
choice coupled with NMD
Consistently highest Dy values in the A5C category were
detected for the exon 18 of the Hps1 gene that its homozygous
loss-of-function form leads to type 1 HPS (Table S3 and Fig. 1D).
Utilization of the u59ss was expected to generate a full-length Hps1
ORF, whereas splicing at the alternative d59ss was predicted to
generate a PTC-containing version of exon 18 (18L) triggering
NMD (Fig. 2A). HPS is currently incurable condition associated
with albinism, prolonged bleeding, ceroid storage and frequently,
a progressive lung disease limiting patients’ lifespan [32–34].
Similar symptoms are observed in the pale ear mouse model
homozygous for a loss-of-function Hps1 allele [32,44].
To test if the expression of this medically important gene was
indeed controlled by AS-NMD in a Ptbp1-dependent manner,
CAD cells pre-treated with siControl, siPtbp1 or siPtbp1/2 were
incubated in the presence of either cycloheximide (CHX), an
inhibitor of protein synthesis also blocking NMD, or an equal
Author Summary
Mammalian gene expression is extensively controlled at
the post-transcriptional level and understanding of the
underlying mechanisms can provide important biomedical
insights. Here we identified a number of novel alternate
splicing (AS) events where the choice between competing
splice sites (ss) is regulated by polypyrimidine tract-
binding protein 1 (Ptbp1/PTB/hnRNP-I). A top-scoring
event was the choice between alternate upstream and
downstream 59ss (u59ss and d59ss) in the Hps1 gene
mutated in patients with type 1 Hermansky-Pudlak
Syndrome (HPS). Preferential utilization of the u59ss in
the presence of Ptbp1 gives rise to stable mRNAs encoding
a full-length Hps1 protein, whereas the d59ss bias
triggered by Ptbp1 down-regulation generates RNA
species cleared by nonsense-mediated decay (NMD). We
show that Ptbp1 functions in this circuitry by activating the
intrinsically weaker u59ss. Brain-enriched Ptbp1 paralog
Ptbp2/nPTB/brPTB stimulated the u59ss utilization but
with a considerably lower efficiency than Ptbp1. We
propose that this mechanism accounts for a tight
correlation between Hps1 with Ptbp1 expression levels
observed in mammalian tissues. Overall, these data expand
our understanding of AS regulation and uncover an AS-
NMD-mediated tracking mechanism ensuring co-expres-
sion of master regulator and its subordinate gene.
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amount of control solution (DMSO) (Fig. 2B–D and S2A). RT-
PCR analysis of these samples using F1/R1 primers (Fig. 2B–C)
confirmed Ptbp1 dependence of the A5C switch and showed that
utilization of the d59ss was significantly elevated in the presence of
CHX (e.g., 2.45-fold increase for siPtbp1-treated samples;
p = 8.461024), consistent with the sensitivity of the corresponding
splice form to NMD. Importantly, RT-quantitative (q) PCR
analyses of the above six samples using F2/R2 primers revealed
significant down-regulation of the Hps1 mRNA steady-state levels
upon Ptbp1 or combined Ptbp1 and Ptbp2 knockdown (Fig. 2D; t-
test p= 0.0017 for siControl vs. siPtbp1 and p= 0.025 for
siControl vs. siPtbp1/2). This down-regulation effect was com-
pletely rescued by CHX treatment (Fig. 2D) indicating that a
major fraction of Hps1 transcripts in the siPtbp1 and siPtbp1/2
samples was subjected to NMD. Similar changes in relative
abundance of the two A5C forms and Hps1 mRNA expression
were detected when we inhibited NMD with siRNA targeting its
key component, Upf1 [17,18] (Fig. S2B–D).
We next wondered if the newly identified post-transcriptional
mechanism could modulate Hps1 expression at the protein level.
Since immunodetection of the endogenous Hps1 protein is
complicated by its relatively low abundance [45], we constructed
a CMV promoter-driven plasmid containing an EGFP ORF fused
in frame with the relevant 39-terminal fragment of the Hps1 gene
(Fig. 2E). CAD cells pre-treated with siControl, siPtbp1 or
siPtbp1/2 siRNAs were transfected with this construct and
analyzed by RT-qPCR and immunoblotting 72 hours post-
transfection. RT-qPCR analysis using EGFP-specific primers
(F3/R3) showed that, similar to the endogenous Hps1 mRNA,
recombinant EGFP-Hps1 transcripts were significantly down-
regulated in the siPtbp1 and siPtbp1/siPtbp2 samples (Fig. 2E)
and underwent corresponding A5C changes (Fig. S2E). On the
Figure 1. Ptbp1 regulates the choice between alternate 59 and 39 splice sites for an extensive set of genes. (A) Data analysis workflow
used to identify regulated A5C and A3C splice junctions. (B) Summary of newly identified events regulated by Ptbp1. The pie chart on the left
classifies A5C and A3C events based on whether Ptbp1 and Ptbp2 bias the AS choice towards upstream or downstream splice site alternative. The
other two pie charts categorize A5C and A3C events according to their effect on mRNA function. (C) CAD cells were treated with Ptbp1-specific siRNA
(siPtbp1), a mixture of siPtbp1 and Ptbp2-specific siRNA (siPtbp2) or control siRNA (siControl) and the expression levels of Ptbp1 and Ptbp2 mRNAs
were analyzed by RT-qPCR. Data are averaged from 3 independent experiments 6SD. (D) RT-PCR validation of examples of the four splicing
topologies (Ptbp1-biased choice of u59ss, d59ss, u39ss or d39ss) in CAD samples treated as in (C). y (percent spliced in) values shown at the bottom
indicate the abundance of the longer splice product isoform as percentage of the total. Data are averaged from 3 independent analyses.
doi:10.1371/journal.pgen.1004771.g001
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other hand, expression levels of a similarly designed control
construct containing EGFP ORF but lacking the Hps1 part were
virtually unchanged upon Ptbp1 and Ptbp1/2 knockdown
(Fig. 2E).
Immunoblotting analysis of the EGFP-Hps1-transfected
samples with an EGFP-specific antibody detected a ,50 kDa
EGFP-Hps1 fusion protein band that was absent in the mock-
transfected sample (Fig. 2F). Importantly, the expression of EGFP-
Hps1 protein decreased upon Ptbp1 and Ptbp1/2 knockdown ,4
and ,7 fold, respectively (ANOVA p=1.461024) (Fig. 2F–G).
Conversely, the control EGFP protein was expressed at virtually
constant levels across all siRNA-treated samples (Fig. 2F–G).
Figure 2. Ptbp1 regulates Hps1 mRNA abundance through AS-NMD. (A) Hps1 gene structure with a close-up of the exon 15-exon 19
segment. The arrowhead indicates premature termination codon (PTC) in the longer (L) isoform of exon 18 and the half-arrows underneath
correspond to PCR primers used in this study. PTC-containing sequence between the alternate u59ss and d59ss is shown at the bottom. (B) CAD cells
transfected with siControl, siPtbp1 or siPtbp1/2 were treated with cycloheximide (CHX) or DMSO (control) and the Hps1 splicing pattern was analyzed
by RT-PCR with F1/R1 primers. Note that knock-down of Ptbp1 alone or together with Ptbp2 promote utilization of d59ss and that the corresponding
PTC-containing splice product is further stabilized by CHX treatment. (C) Relative utilization of the d59ss quantified from (B). (D) RT-qPCR analysis of
the CAD samples from (B) with F2/R2 primers shows that reduced expression of Ptbp1 diminishes Hps1 mRNA expression levels and that this effect is
rescued by CHX. (E–G) 39-terminal part of the Hps1 gene is sufficient for Ptbp1-dependent control at the protein level. (E) Top, expression construct
encoding EGFP-Hps1 fusion protein. Bottom, CAD cells treated with indicated siRNAs were transfected with constructs encoding either EGFP-Hps1 or
unmodified EGFP and splicing patterns of the recombinant transcripts were analyzed by RT-qPCR using F3/R3 primers. (F) Immunoblot analysis of
EGFP-containing proteins in CAD samples prepared as in (E). Ptbp1- and Ptbp2-specific antibodies were used to validate corresponding knockdown
efficiencies, whereas Gapdh-specific antibody was used as a lane loading control. (G) Quantitation of the results in (F). Data in (C, D and G) are
averaged from at least three independent experiments 6SD.
doi:10.1371/journal.pgen.1004771.g002
Regulation of mRNA Abundance by Ptbp1-Controlled 59ss Choice
PLOS Genetics | www.plosgenetics.org 4 November 2014 | Volume 10 | Issue 11 | e1004771
Taken together, these results strongly suggest that Hps1 expression
levels are controlled by AS-NMD mediated by Ptbp1.
Hps1 is co-expressed with Ptbp1 in vivo
We wondered if the newly identified AS-NMD regulation could
account for Hps1 expression patterns in vivo. In line with
published reports [28,46–48], our RT-qPCR analyses showed that
Ptbp1 was expressed across a wide range of adult and embryonic
tissues with the lowest levels observed in brain, heart, skeletal
muscle and testis (Fig. 3A). When the same set of tissues was
assayed for Hps1 mRNA, we detected a striking positive
correlation between Ptbp1 and Hps1 expression levels (Pearson’s
correlation coefficient r=0.951, p = 3.2610216; Fig. 3B and
Fig. 3D). In addition, both the u59ss and the d59ss Hps1 isoforms
were detected in brain, heart, skeletal muscle and testis whereas
only the u59ss isoform was present elsewhere (Fig. 3C). Overall,
there was a strong negative correlation between Ptbp1 levels and
the d59ss utilization efficiency (Pearson’s r=20.626,
p = 6.761024; Fig. 3E). Similar relationships between Ptbp1
expression and incidence of corresponding splice forms were
detected for other newly identified A5C and A3C genes (Fig. S3).
Of note, expression patterns between Hps1 and Ptbp2 mRNA
levels correlated in a negative fashion (Fig. S4). This argued
against a major role of Ptbp2 in shaping Hps1 expression in vivo
and likely reflected the reciprocal relationship between Ptbp1 and
Ptbp2 [28,47,49]. We concluded that Ptbp1 but not Ptbp2 may
control Hps1 abundance across mouse tissues.
Polypyrimidine elements between u59ss and d59ss of
Hps1 exon 18 are necessary for the A5C regulation
To gain insights into the molecular mechanism underlying Hps1
regulation, we prepared a minigene cassette containing Hps1 exon
18, exon 19 and the intervening intron under control of a
doxycycline-inducible promoter [TRE-mini-1819(WT); Fig. 4A].
CAD cells pre-treated with siControl, siPtbp1 or siPtbp1/2 were
transfected with this construct and the minigene-specific splicing
patterns were analyzed by RT-PCR (Fig. 4B). Similar to the
endogenous Hps1 mRNA, minigene-derived transcripts used
preferentially u59ss in the siControl sample and d59ss in the
siPtbp1 and siPtbp1/2 samples (Fig. 4B–C). This indicated that
cis-elements responsible for the dependence of Hps1 splicing
pattern on Ptbp1/2 were located in a vicinity of the regulated exon
18.
Ptbp1 is known to form high-affinity complexes with repeated
UCUC, UCUU, CUCU or UUCU motifs [26,48,50]. Two
pyrimidine-rich stretches (Py1 and Py2) containing consensus
tetramers in pyrimidine-rich contexts occur in Hps1 between the
Ptbp1-regulated u59ss and d59ss (Fig. 4A) and this arrangement is
conserved across mammalian species (Fig. S5). We addressed
possible functional significance of these elements by mutating
either Py1 or Py2 in the TRE-mini-1819 context (Fig. 4A) and
repeating the CAD transfection experiment with the resultant
TRE-mini-1819(Py1-mut) and TRE-mini-1819(Py2-mut) con-
structs. Strikingly, mutation of either of the two Py sequences
was sufficient to completely abolish the A5C regulation with the
Figure 3. Hps1 is co-expressed with Ptbp1 in vivo. (A) RT-qPCR analysis of Ptbp1 expression in embryonic (E12.5) and adult mouse tissues.
Expression level in adult mouse liver is set to 1. (B) RT-qPCR quantitation of Hps1 mRNA expression levels in the same set of mouse tissues as in (A)
averaged from three independent experiments 6SD. (C) RT-PCR analysis of the Hps1 exon18-exon19 tissue-specific splicing patterns. Relative
abundances of the d59ss-spliced products [y(d59ss)] averaged from two independent experiments 6SD are indicated at the bottom. (D–E) Scatter
plots showing significant positive correlation between Ptbp1 and Hps1 mRNA expressions and negative correlation between Ptbp1 expression and
Hps1 y(d59ss) values.
doi:10.1371/journal.pgen.1004771.g003
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splicing pattern shifting towards d59ss in siControl, siPtbp1 and
siPtbp1/2 samples (Fig. 4B–C).
However, when we assayed splicing of the minigene-encoded
transcripts in CAD cells over-expressing comparable amounts of
recombinant Ptbp1 or Ptbp2 proteins (Fig. S6A), u59ss utilization
was partially restored in TRE-mini-1819(Py1-mut) and, to a lesser
extent, TRE-mini-1819(Py2-mut) (Fig. S6B–C). Notably, recom-
binant Ptbp1 rescued u59ss more efficiently than Ptbp2 (Fig. S6B–
C) and transcripts derived from the TRE-mini-1819(Py1-mut/
Py2-mut) minigene lacking both Py sequences were constitutively
spliced at d59ss both in the control and the Ptbp1- or Ptbp2-over-
expressing samples (Fig. S6B–C).
Overall, these experiments suggest that both Py sites are
required to orchestrate Hps1 A5C regulation under physiological
conditions. Of the two sites, Py2 plays a more decisive role than
Py1 and Ptbp1 is a noticeably stronger regulator than Ptbp2.
Ptbp1 binding to Py1 and Py2 elements regulates the
A5C
To test if Ptbp1 directly interacted with Py1 and Py2 sequences,
we carried out a biotinylated RNA pull-down assay (Fig. 4D).
Interaction between Ptbp1 and a wild-type Hps1 probe compris-
ing both Py1 and Py2 sites was readily detectable by this approach
Figure 4. Ptbp1 binds to pyrimidine-rich sequences between u59ss and d59ss and directly regulates Hps1 A5C. (A) Minigene construct
encoding Hps1 exon 18-intron 18-exon 19 segment. Putative Ptbp1 binding motifs, Py1 and Py2, and their mutated versions are depicted below. (B)
CAD cells treated with indicated siRNAs were transfected with either the wild-type (WT) TRE-mini-1819 construct or its Py1-mut or Py2-mut
derivatives and analyzed by RT-PCR using F1/R4 primers. Considerable accumulation of minigene-specific d59ss-spliced transcripts in this experiment
and Fig. S6B is likely a result of their NMD resistance due to the lack of ORF. (C) Quantitation of the relative abundances of the d59ss-spliced form
[y(d59ss)] in (B) averaged from three independent experiments 6SD. (D) Top, Ptbp1-RNA binding assay. Bottom, immunoblot analysis showing
readily detectable Ptbp1 interaction with the wild-type mini-1819 RNA, reduced interaction with the Py1-mut mini-1819 RNA and severely diminished
interaction with the Py2-mut mini-1819 RNA. NTC is a no-template control. (E) Splicing of the Hps1 or AdV RNA substrates was assayed in vitro using
control-treated or Ptbp1-immunodepleted NEs and the reaction products were analyzed using RT-PCR at the 0- and 60-minute time points. (F)
Quantitation of the results from (E) showing relative abundance of the d59ss-spliced form [y(d59ss)] averaged from two independent experiments
6SD. (G) Ptbp1-immunodepleted splicing reactions were supplemented with indicated amounts of purified recombinant Ptbp1 protein and the
reaction products were analyzed as in (E). (H) Relative abundance of the d59ss-spliced form [y(d59ss)] in (G) averaged from two independent
experiments 6SD.
doi:10.1371/journal.pgen.1004771.g004
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(Fig. 4D). However, mutation of either Py1 or Py2 noticeably
reduced this interaction, with a greater reduction in binding
affinity observed upon inactivation of Py2 (Fig. 4D and Fig. S6D).
To examine whether Ptbp1 recruitment to the Py sites was
responsible for biasing the Hps1 A5C towards u59ss, we prepared
a synthetic RNA comprising the mini-1819(WT) cassette and
analyzed splicing of this substrate in vitro using HeLa S3 nuclear
extract (NE; Fig. 4E). After a 60-min incubation at 30uC, two
splicing products were detected by RT-PCR using F1/R1 primers
corresponding to splicing at the u59ss (,65%) and the d59ss
(,35%) (Fig. 4E). Notably, when we immunodepleted Ptbp1 from
the NE and repeated the experiment, the d59ss utilization
increased to ,90% (t-test, p = 5.261023; Fig. 4E–F). Ptbp1
depletion had no effect on the efficiency of constitutive splicing
of a control adenovirus-derived RNA substrate (AdV) (Fig. 4E).
To further ensure that the change in the Hps1 splicing upon Ptbp1
withdrawal was a specific effect, we supplemented immunode-
pleted NE with purified recombinant Ptbp1 protein and repeated
the analysis. Notably, the addition of increasing Ptbp1 amounts led
to a progressive decline in the d59ss utilization and a correspond-
ing increase in the u59ss utilization (Fig. 4G–H). Less efficient
u59ss rescue was observed when we used purified recombinant
Ptbp2 instead of Ptbp1 (Fig. S7).
Thus, Ptbp1 binds to the Py1 and Py2 sequences within exon
18/L and directly biases the choice between the two alternate 59
splice sites towards u59ss. Similar to our above results, Ptbp2 is less
efficient than Ptbp1 in promoting u59ss utilization in vitro.
Ptbp1 stimulates u59ss usage
Two alternative models could account for the above results: (1)
direct activation of u59ss by Ptbp1 or (2) repression of d59ss
indirectly biasing the choice towards u59ss. To distinguish between
these possibilities, we prepared three TRE-mini-1719 minigenes
comprising Hps1 exons 17, 18 and 19 along with the intervening
introns (Fig. 5A). Of these, TRE-mini-1719(WT) contained intact
exon 18 u59ss and d59ss and therefore was expected to be
regulated similarly to the TRE-mini-1819(WT) minigene above.
In the other two constructs, TRE-mini-1719(u59ss-mut) and TRE-
mini-1719(d59ss-mut), the corresponding sites were inactivated by
mutations thus allowing us to test whether Ptbp1/2 had an effect
on utilization of the only remaining 59ss (Fig. 5A).
We introduced these constructs into CAD cells pre-treated with
siControl, siPtbp1 or siPtbp1/2 and analyzed the samples
72 hours post-transfection by multiplex RT-PCR using a combi-
nation of two primer pairs (F1/R5 and F4/R4) designed to
measure the ratio between expression levels of spliced and total
minigene-specific transcripts (Fig. 5B). Three distinct RT-PCR
products were detectable in TRE-mini-1719(WT) samples with the
F4/R4 ‘‘normalizer’’ band at the bottom and the u59ss- and d59ss-
spliced variants of the F1/R5 amplicon at the top (Fig. 5B). As
expected, the ratio between the two top bands changed upon
Ptbp1 or Ptbp1/2 knockdown indicating an increased usage of the
d59ss (Fig. 5B). TRE-mini-1719(u59ss-mut) and TRE-mini-
1719(d59ss-mut) samples gave rise to two products: the F4/R4
normalizer and either the d59ss- or u59ss-spliced variant of the F1/
R5 amplicon, respectively (Fig. 5B). Importantly, down-regulation
of Ptbp1 alone or in combination with Ptbp2 had no detectable
effect on the d59ss-spliced product/normalizer ratio for TRE-
mini-1719(u59ss-mut) but significantly reduced the u59ss-spliced
product/normalized ratio in the TRE-mini-1719(d59ss-mut) sam-
ples (Fig. 5B–C).
Similar results were obtained when we re-analyzed the
above samples by RT-qPCR using splice junction-specific primers
designed to distinguish between u59ss and d59ss use (Fig. S8A–D).
Indeed, siPtbp1 and siPtbp1/2 up-regulated the d59ss-spliced
products and diminished the abundance of the u59ss-spliced ones
in the WT, whereas d59ss utilization was not affected by siPtbp1
and siPtbp1/2 in the u59ss-mut transcripts. On the other hand,
u59ss was clearly repressed by siPtbp1 and siPtbp1/2 in the d59ss-
mut transcripts. Thus, Ptbp1 appeared to activate the u59ss rather
than repress the d59ss.
To test whether this could be a direct effect, we carried out an in
vitro splicing assay with a synthetic mini-1819 RNA substrate
mutated at the d59ss position [mini-1819(d59ss-mut)] and analyzed
the reaction products by RT-PCR (Fig. 5D). As expected, a single
u59ss-derived splice form was detected after a 60-min incubation
with HeLa S3 NE (Fig. 5E). The mini-1819(d59ss-mut) splicing
efficiency was dramatically diminished when we immunode-
pleted Ptbp1 from the NE (,10-fold down-regulation; t-test
p = 1.161026; Fig. 5E–F). Analysis of the reaction products by
RT-qPCR confirmed that this reduction in splicing efficiency
(t-test p = 1.461026; Fig. S8H) is accompanied by a reciprocal
increase in the pool of unspliced RNA (Fig. S8F). Importantly,
supplementing immunodepleted NE with purified recombinant
Ptbp1 rescued mini-1819(d59ss-mut) splicing in a dose-dependent
manner (Fig. 5G–H and Fig. S8I). We concluded that Ptbp1
regulates Hps1 A5C by stimulating the u59ss.
Regulation of Hps1 AS depends on difference between
u59ss and d59ss strengths
Our data so far suggested that Ptbp1 interacts with Py1 and Py2
sequences within exon 18 and enhances u59ss utilization.
Interestingly, predicted splicing strength of u59ss was lower than
that of d59ss (scores Su59ss = 76.1 vs. Sd59ss = 94.1 obtained
using Analyzer Splice Tool server http://ibis.tau.ac.il/ssat/
SpliceSiteFrame.htm; [51,52]) and similar differences were
detected in other mammalian species (Table S5). To test if this
feature was important for the regulation, we generated a series of
modified TRE-mini-1819 minigenes where the natural u59ss was
substituted with the d59ss or/and the d59ss was substituted with the
u59ss [TRE-mini-1819(d59ss/d59ss), TRE-mini-1819(u59ss/u59ss)
and TRE-mini-1819(d59ss/u59ss); Fig. 6A]. All of these permuta-
tions lowered the DS=Sd59ss-Su59ss difference between the two 59ss
strengths. Notably, when we transfected CAD cells with the
corresponding minigenes, the upstream 59 splice position was
constitutively selected in all siRNA-treated samples (Fig. 6B–C).
Similar effects were observed when we weakened the u59ss or
strengthened the d59ss by substituting them with synthetic 59ss
sequences (Fig. S9). These results are consistent with the model
that Hps1 A5C regulation requires u59ss to be weaker than d59ss.
The mechanism regulating Hps1 A5C may recur in other
genes
We finally asked whether other A5C events uncovered in our
bioinformatics screen featured pyrimidine-rich sequences between
u59ss and d59ss and a weaker u59ss. To this end, we measured
density of putative Ptbp1-binding tetramers (UCUC, UCUU,
UUCU, CUCU) between u59ss and d59ss in three classes of A5C
events: (1) biased towards u59ss in the presence of Ptbp1, (2) biased
towards d59ss in the presence of Ptbp1 and (3) 100 randomly
selected instances of Ptbp1-insensitive A5C (Fig. 7A and Table
S6). This analysis showed that the incidence of Ptbp1 motifs was
significantly higher in the class 1 events compared to the class 3
control (KS test, p = 0.0041) whereas the class 2 events did not
significantly differ from the control (KS test, p = 0.25).
Notably, when we calculated A5C event-specific differences
between predicted 59ss strengths (http://ibis.tau.ac.il/ssat/
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SpliceSiteFrame.htm; [51,52]), distribution of the DS=Sd59ss-Su59ss
values had a significant positive bias for the class 1 (Wilcoxon rank
sum test, p = 0.044) but not for the class 2 events (Wilcoxon rank
sum test, p = 0.51) (Fig. 7B). Thus, the molecular logic underlying
Hps1 regulation might be common amongst A5C events with
Ptbp1-induced u59ss bias.
Figure 5. Ptbp1 functions by stimulating u59ss usage rather than repressing d59ss. (A) TRE-mini-1719 minigene constructs used in this
experiment. Red crosses indicate mutational inactivation of the corresponding splice sites. (B) CAD cells treated with indicated siRNAs were
transfected with either WT or mutated (u59ss-mut or d59ss-mut) TRE-mini-1719 constructs and analyzed by multiplex RT-PCR combining two primer
pairs, F1/R5 and F4/R4, to detect the ratio between spliced and total minigene-specific transcript levels. (C) Relative splicing efficiencies of TRE-mini-
1719(u59ss-mut) the TRE-mini-1719(d59ss-mut) samples in (B) calculated as a ratio between spliced and total transcript abundance. Data are averaged
from three independent experiments 6SD. (D–E) Splicing of mini-1819(d59ss-mut) RNA was assayed in the presence of control-treated or Ptbp1-
immunodepleted NE and the reaction products were analyzed by multiplex RT-PCR. (F) Quantitation of the results from (E), represented as average
splicing efficiency from two independent experiments, 6SD. (G) Ptbp1-immunodepleted reactions were rescued with increasing concentration of
recombinant Ptbp1 protein and analyzed by RT-PCR. (H) Quantitation of the results from (G), represented as splicing efficiency averaged from two
independent experiments, 6SD.
doi:10.1371/journal.pgen.1004771.g005
Figure 6. Hps1 regulation depends on u59ss being weaker than d59ss. (A) TRE-mini-1819 minigenes containing either a wild-type (top) or a
permuted arrangement of the two 59ss. (B) CAD cells pre-treated with indicated siRNAs were transfected with the TRE-mini-1819 constructs
introduced in (A) and analyzed by RT-PCR using minigene-specific primers F1/R4. Note that the upstream 59 splice position is constitutively used in all
permuted minigene samples. (C) Utilization of the topologically downstream 59 splice site [y(down)] in (B) averaged from three independent
experiments 6SD.
doi:10.1371/journal.pgen.1004771.g006
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Discussion
Mammalian gene expression is extensively controlled at the
post-transcriptional level and understanding molecular mecha-
nisms underlying this regulation can generate valuable biomedical
insights. In this study, we interrogated transcriptome-wide RNA-
seq data and uncovered a number of functionally diverse Ptbp1-
dependent A5C and A3C events. We demonstrated that Ptbp1
directly controls the choice between the u59ss and the d59ss in
Hps1 exon 18 (Fig. 7C). Both Ptbp1 binding motifs (Py1 and Py2)
were required for the regulation at physiological Ptbp1 concen-
trations (Fig. 4A–C) as well as for optimal binding of Ptbp1 to
corresponding RNA probes (Fig. 4D and Fig. S6D). Moreover, the
splicing switch could be recapitulated by altering Ptbp1 concen-
tration in vitro (Fig. 4E–H and Fig. S7). The Ptbp1 paralog Ptbp2
contributed little to the Hps1 A5C control (Fig. S4, Fig. S6A–C
and Fig. S7).
Previous work on A5C mechanisms has suggested that
recruitment of an hnRNP protein between two alternate 59ss
may bias the AS choice towards the u59ss by either activating this
site directly, repressing its d59ss competitor or a combination of the
two effects [11–13]. In the case of Hps1, Ptbp1 appears to achieve
this effect by directly stimulating a relatively weak u59ss rather
than repressing its intrinsically stronger d59ss competitor (Fig. 5,
Fig. 6 and Fig. S9). Since A5C targets with Ptbp1-induced u59ss
bias show enrichment of pyrimidine-containing motifs between
u59ss and d59ss and their u59ss tends to be weaker than and the
d59ss (Fig. 7A–B), Hps1-like A5C regulation may recur in other
genes.
What could be the mechanism allowing Ptbp1 to activate the
Hps1 u59ss? One possibility might involve stimulation of U1
snRNP recruitment to the u59ss by the Ptbp1 complex assembled
at the Py1 and Py2 sequences. Similar strategies have been
proposed to mediate activation of an upstream 59ss by the hnRNP-
like protein TIA-1 [13,53] and other RNA-binding proteins
interacting with downstream intronic splicing enhancers [9,54].
Moreover, Ptbp1 complex assembled on the c-Src pre-mRNA in
the vicinity of the AS exon N1 has been shown to form contacts
with U1 recruited to the N1 59ss [55]. Although this leads to
repression of N1 splicing, interaction between Ptbp1 and U1
might result in opposite effects in other AS contexts with distinct
structures of the ternary complex between Ptbp1, pre-mRNA and
U1. Similar to position-specific effects on AS observed for other
RNA-binding proteins [56–58], Ptbp1 tends to function as a
splicing repressor when recruited upstream or/and within AS
exons and as an activator when bound to downstream sequences
[48,59]. Additional characterization of the Hps1 A5C may shed
new light on this poorly understood phenomenon.
Intriguingly, functionality of the Hps1 A5C appears to rely on a
finely tuned balance between the u59ss and d59ss strengths, since
all mutations strengthening the relatively weak u59ss or weakening
the relatively strong d59ss lead to constitutive utilization of the
u59ss (Fig. 6 and Fig. S9). It is somewhat surprising that
recombinant Hps1 transcripts containing two equally strong or
equally weak 59ss fail to generate a mixture of the two splice
isoforms upon Ptbp1 and Ptbp2 withdrawal. This might hint at the
existence of additional factors biasing the A5C towards the u59ss.
Interestingly, u59ss rescue by purified Ptbp1 in Ptbp1-depleted in
vitro splicing reactions was incomplete in a subset of our assays
(e.g., compare Fig. 5E and Fig. 5G). This would be consistent with
direct interaction of a hypothetical u59ss-stimulating factor with
Ptbp1 protein. We plan to address this interesting prediction in our
future studies.
The AS-NMD circuitry identified in our work (Fig. 7C) may
account for tissue-specific Hps1 expression. We show that splicing
at the u59ss gives rise to functional Hps1 ORF whereas utilization
of the d59ss generates NMD-susceptible transcripts (Fig. 2). Since
Ptbp1 is required for selecting the u59ss alternative, this
mechanism likely ensures a strong positive correlation between
Hps1 and Ptbp1 expression levels across tissues (Fig. 3). Type 1
HPS caused by homozygous loss-of-function mutations in Hps1 is
typically manifested by reduced pigmentation, prolonged bleeding
and lysosomal storage defects in many tissues. Further complica-
tions include inflammatory bowel disease and life-limiting
pulmonary fibrosis [32–34,44]. Despite the multi-organ nature
of this syndrome, HPS patients and pale ear mice do not typical-
ly develop neurological, cardiac or muscular problems
Figure 7. Hps1-like A5C regulation may recur in other genes. (A) Empirical cumulative distribution function (ECDF) plot of Ptbp1 motif
density within exon segments demarcated by the two 59ss alternatives in A5C genes. (B) Density plot of the difference between d59ss and u59ss
strengths. Median values are shown by vertical colored lines. (C) Model of Ptbp1-dependent AS-NMD regulation of Hps1 expression. Ptbp1 stimulates
usage of the intrinsically weak u59ss thus giving rise to functional Hps1 mRNA. The choice is shifted towards the naturally strong d59ss in neurons and
muscle cells where Ptbp1 is expressed at relatively low levels. This destabilizes Hps1 mRNA through NMD.
doi:10.1371/journal.pgen.1004771.g007
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[32–34,44,60]. This would be consistent with the naturally low
Hps1 levels in tissues expressing little Ptbp1.
Ptbp1 has been previously shown to regulate expression levels of
several genes through AS coupled with NMD or nuclear retention
and elimination (NRE) of aberrantly spliced transcripts [28–30].
However, in all of these cases Ptbp1 down-regulation increased
steady-state levels of the corresponding mRNAs in the neuronal
lineage. Thus, Hps1 provides a remarkable example of AS-NMD
circuitry enabling tight co-expression of a target gene and its post-
transcriptional master regulator. One possible advantage of this
strategy could be ‘‘de-noising’’ of the Hps1 expression outputs in
the presence of Ptbp1, since Ptbp1 own expression is stabilized by
an auto-regulatory AS-NMD feedback loop [27]. On the other
hand, this may allow developmental dynamics of Hps1 to be
synchronized with expression changes in other Ptbp1 targets thus
maximizing the overall coordination of cellular differentiation
process.
In conclusion, our work uncovers a large set of Ptbp1-controlled
A5C and A3C events and provides molecular insights into
mechanism regulating expression output of the disease-related
Hps1 gene. We predict that further examples of the master
regulator tracking strategy described here for Hps1 will be
identified in the future.
Materials and Methods
Plasmids
pGEM3Zf(+) and pEGFP-C1 vectors were from Promega and
Clontech, respectively. AdML-M3 construct encoding an adeno-
virus-specific splicing substrate (Addgene #11244) and pEM275
and pEM288 plasmids encoding FLAG-tagged Ptbp1 and Ptbp2,
respectively, were described previously [28,61]. New constructs
were generated using standard molecular cloning techniques and
enzymes from NEB as outlined in Table S7. Site-specific
mutagenesis was done using KAPA HiFi DNA polymerase (KAPA
Biosystems) and corresponding mutagenic primers (Table S8). All
plasmid maps and sequences are available on request.
Cell cultures
CAD cells (Cath.a-derived mouse neuroblastoma) [62] were
cultured in Dulbecco’s Modified Eagle Medium/High Glucose
(DMEM; GIBCO, USA), supplemented with 11% FetalClone III
Serum (Hyclone, USA), 1 mM sodium pyruvate (GIBCO, USA),
100 IU/ml penicillin and 100 mg/ml streptomycin, at 37uC in the
presence of 5% CO2. For transfection experiments, cells were
plated in the CAD medium without antibiotics at a density of
46105 cells per well of a tissue culture 6-well plate. Twelve hours
post-plating, cells were transfected with corresponding siRNAs
(ThermoScientific Dharmacon, USA) using Lipofectamine RNAi-
MAX (Invitrogen, USA). Following 36-hour incubation, cell
cultures were typically re-transfected with 1 mg of a minigene
plasmid using Lipofectamine 2000 and incubated for another
36 hours prior to RNA harvest. In some experiments, cells were
treated with either 100 mg/ml of CHX dissolved in DMSO or
DMSO control for 8 hours. In the FLAG-Ptbp1 and FLAG-Ptbp2
over-expression experiments, 35 ng of pEM275 or 90 ng of
pEM288 was co-transfected with 100 ng of Hps1 TRE-mini-1819
minigene and the total DNA amount was adjusted to 1 mg with an
EGFP-encoding control plasmid (pCIG) and incubated for
48 hours.
RT-PCR and RT-qPCR
Total RNA was harvested from adherent cells using Trizol
(Invitrogen). RNA was subsequently treated with 50 units/ml of
RQ1 DNase (Promega) at 37uC for 1 hour to eliminate traces of
genomic DNA. First-strand cDNA synthesis (RT) was typically
performed in 10 ml reactions containing 2.5 mg of total RNA,
50 pmol of a random decamer primer (N10), 40 units of
rRNAsin (Promega) and 100 units of SuperScript III reverse
transcriptase (Invitrogen) at 50uC for 1 hour. Regular PCRs
were carried out using Taq DNA polymerase (KAPA Biosys-
tems) and amplification products were resolved by gel electro-
phoresis in 2% or 3.5% agarose gels. Quantitative PCR (qPCR)
assays were done in triplicate using SYBR FAST qPCR Master
Mix (KAPA Biosystems) and a StepOnePlus real-time PCR
system (Applied Biosystems) and the signals were normalized to
Gapdh mRNA levels. Relevant primer sequences are provided
in Table S7.
Biotinylated RNA pull-down assays
RNA probes were generated by transcribing linearized plasmid
DNA in vitro with T7 polymerase (Promega) and biotin RNA
labeling mix (Roche) for 2 hours at 37uC. Reactions were stopped
by adding 1 unit of RQ1 DNase per 1 mg of template DNA and
incubating the mixtures at 37uC for 15 min. Biotinylated RNAs
were then extracted using phenol-chloroform (1:1) mixture,
precipitated with ethanol and resuspended in DEPC-treated
water. Pull-down assays were carried out by incubating 2 mg of
purified RNA probes in 20 ml of buffer D (20 mM HEPES,
pH 7.9, 100 mM KCl, 20% Glycerol, 0.5 mM DTT and 0.2 mM
EDTA) supplemented with 80 ng yeast tRNA, 2.5 mg heparin, 40
units of rRNAsin (Promega) and 50% HeLa S3 NE (vol/vol;
dialyzed against buffer D; ,100 mg protein in total) for 30 min at
room temperature. RNA-protein complexes were then incubated
with 20 ml of Streptavidin Sepharose Beads (Sigma) pre-washed in
buffer D for 1 hour at 4uC. The beads were then washed thrice
with buffer D and the RNA-associated proteins were eluted by
boiling the beads for 10 min in 30 ml of 16 SDS PAGE sample
buffer (0.0625 M Tris-HCl pH 6.8, 2% SDS, 5% b-mer-
capthoethanol, 10% glycerol and 0.01% bromophenol blue) and
subsequently analyzed by immunoblotting.
In vitro splicing assay
Splicing reactions (20 ml) contained 200 ng of unlabeled splicing
substrate RNA prepared by in vitro transcription [29], 2 ml of 106
splicing reaction buffer (120 mM HEPES, pH 7.9, 32 mM MgCl2
and 725 mM KCl), 1 mM ATP (NEB), 20 mM phosphocreatine
(Sigma) 2.5% poly(vinyl alcohol) (Sigma, MW 30–70K), 1 mM
DTT, 10 units of rRNAsin (Promega) and 30% HeLa S3 NE (vol/
vol; ,60 mg protein; dialyzed against buffer D). Following
incubation at 30uC for 60 min the reactions were stopped by
the addition of 200 ml of PK buffer (10 mM Tris-HCl pH 7.4, 1%
SDS, 150 mM NaCl and 10 mM EDTA) and 0.25 mg/ml
proteinase K (Fermentas) and incubated for another 15 min at
37uC. Splice products were extracted with phenol-chloroform
(1:1), precipitated with ethanol, dissolved in DEPC-treated water
(Invitrogen) and analyzed by RT-PCR using corresponding
primer pairs (Table S7). Adenovirus-specific splicing was assayed
using EMO2619/2622 primers (Table S7). In some experiments,
NE was immunodepleted for Ptbp1. For this purpose, 40 mg of
mouse monoclonal anti-PTBP antibody (Invitrogen, clone 1) was
incubated with 40 ml of protein G Sepharose beads (GE
Healthcare) overnight at 4uC with continuous rotation. Beads
were subsequently washed thrice with buffer D and incubated with
50 ml of HeLa S3 NE for another 4 h at 4uC with rotation. Ptbp1-
depleted NE was then recovered by pelleting the beads at
3,000 rpm for 2 min.
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Immunoblotting
Proteins were extracted from PBS-washed adherent cells using
NP40 buffer [20 mM Tri-HCl, pH 7.5, 150 mM NaCl, 5 mM
EDTA, 10% glycerol, 1% Nonidet P-40, 1 mM phenylmethane-
sulfonyl fluoride and recommended concentration of cOmplete
EDTA-free protease inhibitor cocktail (Roche; one tablet per
50 ml)] and quantified using a BCA protein assay kit (Thermo
Scientific). Proteins were then separated by 4–20% gradient SDS-
PAGE (Bio-Rad), electrotransferred to nitrocellulose membranes
and analyzed using the following primary antibodies: mouse
monoclonal anti-Ptbp1 (1:1000, Invitrogen), mouse monoclonal
anti-Ptbp2 (1:20000; a gift from R. Darnell), mouse monoclonal
anti-GFP (1:2000, Invitrogen), mouse monoclonal anti-FLAG M2
(1:1000, Sigma), mouse monoclonal anti-Gapdh (1:10000, Am-
bion). Immunoblot signals were visualized using corresponding
secondary antibodies conjugated with horseradish peroxidase (GE
Healthcare) and Immobilon Western ECL reagents (Milipore).
Bioinformatics
To identify A5C and A3C events, fastq RNA-seq files for CAD
cells treated with siControl, siPtbp1 or siPtbp1/2 ([29]; NCBI
Gene Expression Omnibus accession number GSE37933) were
analyzed using TopHat aligner [63] and mm9 mouse genome
assembly. The aligned junction read files were then processed
using in-house Perl scripts (Dataset S1) designed to identify all
possible pairs for A5C (u59ss-c39ss and d59ss-c39ss) and A3C (c59ss-
u39ss and c59ss-d39ss) junctions across experimental samples.
Junction reads corresponding to cassette exons were depleted by
requesting that u59ss in A5C and d39ss in A3C pairs map to a
known exon present in the UCSC gene, RefSeq gene or mRNA
libraries (http://genome.ucsc.edu/). A5C and A3C pairs under-
going significant changes were identified by Fisher’s exact test
using R (http://CRAN.R-project.org/doc/FAQ/R-FAQ.html)
(Dataset S1).
Ethics statement
All mouse work was conducted according to protocol approved
by the Institutional Animal Care and Use Committee (IACUC) of
Nanyang Technological University, Singapore. No surviving
procedures were used. Mice were euthanized using isoflurane
overdose procedure as recommended by IACUC.
Supporting Information
Figure S1 Optimization of the A5C and A3C discovery pipeline
and validation of newly identified events. (A) To make sure our
A5C/A3C analysis pipeline performed adequately, we first
analyzed training RNA-seq data from CAD and L929 cells
expected to exhibit markedly different AS patterns. This
uncovered 195 A5C and 171 A3C significant cell line-specific
events (p,0.05, Fisher’s exact test) with apparent differences in the
isoform-specific percent spliced in statistic (y [7]) exceeding 5%
(Tables S1 and S2). Satisfyingly, all 8 examples selected for reverse
transcriptase (RT)-PCR validation showed readily detectable
differences in spicing patterns between the two cell lines. (B)
RT-PCR validation of a subset of Ptbp1-regulated A5C and A3C
events. Other examples are presented in Fig. 1D. y values show
the abundance of the longer splice form as a percentage of the
total averaged from 3 experiments.
(TIF)
Figure S2 Ptbp1 regulates Hps1 mRNA abundance through
AS-NMD. (A) Immunoblot analysis of CAD cells treated as in
Fig. 2B with Ptbp1- and Ptbp2-specific antibodies. Gapdh-specific
antibody was used as a lane loading control. (B) CAD cells pre-
treated with siControl, siPtbp1 or siPtbp1/2 were transfected with
siUpf1 or siControl and the Hps1 splicing pattern was analyzed by
RT-PCR with F1/R1 primers. (C) Relative utilization of the d59ss
form in (B). (D) RT-qPCR quantitation of the Hps1 and Upf1
expression in CAD samples treated as in (B). (E) Hps1-EGFP-
specific A5C patterns in samples introduced in Fig. 2E were
analyzed by RT-PCR with F6/R1 primers.
(TIF)
Figure S3 Ptbp1-dependent A5C and A3C events are regulated
in a tissue-specific manner. AS patterns of indicated mRNAs in
adult mouse liver, cerebellum and cortex were analyzed by RT-
PCR. Note that tissue-specific splice form preferences are
consistent with relatively high expression of endogenous Ptbp1
in liver and low expression in brain (see Fig. 3A). y values
for the abundance of the longer isoform are averaged from 3
experiments.
(TIF)
Figure S4 Tissue-specific patterns of Ptbp2 expression. (A) RT-
qPCR analysis of Ptbp2 expression in embryonic (E12.5) and adult
mouse tissues. Expression level in adult mouse liver is set to 1.
Data are averaged from three independent experiments 6SD. (B)
Scatter plot showing a modest but significant negative correlation
between Hps1 and Ptbp2.
(TIF)
Figure S5 Conservation of the Hps1 exon 18/L cis-elements
across mammals. Sequences labeled in red are consensus Ptbp1-
binding motifs occurring within pyrimidine-rich contexts, Py1 and
Py2. Also shown are the u59ss and the d59ss as well as the
premature termination codon (PTC).
(TIF)
Figure S6 Contribution of the Py1 and Py2 sequences to the
Hps1 A5C regulation. (A) Immunoblot analysis showing that CAD
cells transfected with optimized plasmid blends (see Materials and
Methods) express comparable amounts of FLAG-tagged Ptbp1
and Ptbp2. (B) CAD cells expressing either control or FLAG-
Ptbp1- or FLAG-Ptbp2-encoding constructs as in (A) were co-
transfected with indicated TRE-mini-1819 minigenes and ana-
lyzed by RT-PCR using F1/R4 primers. (C) Quantitation of the
results in (B). (D) Quantitation of the relative amount of
Ptbp1 bound to Hps1 RNA probes as described in Fig. 4D. Data
in (C and D) are averaged from three independent experiments
6SD.
(TIF)
Figure S7 Ptbp1 is more efficient than Ptbp2 in regulating the
Hps1 A5C in vitro. (A) Coomassie-stained SDS-PAGE analysis of
purified recombinant Ptbp1 and Ptbp2 proteins. (B) The effect of
increasing amounts of recombinant Ptbp1 and Ptbp2 on in vitro
splicing of a wild-type Hps1 RNA substrate in Ptbp1-immunode-
pleted NE. (C) Quantitation of the data in (B) showing significantly
stronger down-regulation of the d59ss-spliced products in reactions
containing recombinant Ptbp1 as compared to those supplement-
ed with Ptbp2. Data are averaged from two independent
experiments 6SD.
(TIF)
Figure S8 Quantitative analyses of Hps1 A5C in vivo and in
vitro. (A–D) RT-qPCR quantitation of (A–B) u59ss-spliced and (C–
D) d59ss-spliced products for indicated TRE-mini-1719 minigenes
expressed in CAD cells as outlined in Fig. 5B. Note that siPtbp1
and siPtbp2 reduce u59ss utilization in TRE-mini-1719(d59ss-mut)
samples but have no detectable effect on d59ss utilization in
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TRE-mini-1719(d59ss-mut) samples. (E–F) RT-qPCR quantita-
tion of residual unspliced mini-1819(d59ss-mut) RNA substrate
after incubating it for 60 minutes with control- or Ptbp1-depleted
NEs. Note that significantly more mini-1819(d59ss-mut) RNA
substrate remains unspliced in the Ptbp1-depleted samples. (G–I)
RT-qPCR quantitation of spliced products for experiments
described in Fig. 5E and Fig. 5G, respectively. Data in (B, D, F,
H and I) are averaged from three independent experiments 6SD.
(TIF)
Figure S9 Hps1 regulation depends on u59ss being weaker
than d59ss. (A) TRE-mini-1819 minigenes with mutated u59ss or
d59ss. (B) Strengths of the wild-type and mutant 59ss sequences
predicted by Analyzer Splice Tool (http://ibis.tau.ac.il/ssat/
SpliceSiteFrame.htm; [51,52]) (C) siRNA-treated CAD cells were
transfected with the TRE-mini-1819 constructs introduced in (A)
and analyzed by RT-PCR using minigene-specific primers F1/R4.
(D) Usage of topologically downstream splice site [y(down)] in (C)
averaged from two independent experiments 6SD.
(TIF)
Table S1 A5C events differentially regulated between CAD and
L929 cells.
(XLSX)
Table S2 A3C events differentially regulated between CAD and
L929 cells.
(XLSX)
Table S3 A5C events regulated by Ptbp1 in CAD cells.
(XLSX)
Table S4 A3C events regulated by Ptbp1 in CAD cells.
(XLSX)
Table S5 Difference between u59ss and d59ss strengths in
mammalian Hps1 genes.
(XLSX)
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